Little Green Pharma
Little Green Pharma (LGP) has signed a non-exclusive five-year deal with Danish distributor Balancial for the sale and distribution of LGP-branded cannabis oil and flower medicines in Denmark.
Managing director Fleta Solomon said the deal was another milestone in the company’s strategy of growing its market share in key European medicinal cannabis markets following the establishment of distribution pathways in Germany, the UK and France.
Emyria has secured firm commitments from sophisticated and strategic investors in a well-supported A$5 million placement
Funds will be used to advance clinical trials for mental health treatment EMD-003 and EMD-004, for irritable bowel syndrome, as a first step towards registration with the TGA.
The company will also use the funds to define US FDA regulatory pathways for its growing drug-development programs, scope a psychedelic-assisted therapy clinical trial in partnership with Mind Medicine Australia, and support additional drug-development programs for new indications.
Health House International
Pharmaceutical distributor Health House International has entered into a non-exclusive distribution deal with UK-based Dragonfly Biosciences for the launch of Dragonfly’s medicinal cannabis products in pharmacies across Australia.
Health House plans to launch the first CBD products in Australia by mid-2021.
Dragonfly is a leading UK manufacturer of a seed-to-shelf range of CBD oils and skincare products available from high-street retailers in narrow and broad-spectrum ranges.
Australian Primary Hemp
Australian Primary Hemp (APH) has announced a second retail distribution deal with Coles under which the supermarket chain will carry five additional products from APH’s Mt. Elephant range in stores across Australia from July 2021.
Coles will stock Elephant Almond and Buckwheat Pancakes in chocolate and vanilla and Superfood Protein Balls in choc cherry, chocolate and hazelnut.
The move follows an agreement for Coles to stock APH’s Mt. Elephant Mylk products announced in March. APH predicted sales revenue of around A$3 million annually from what it said was the company’s largest distribution agreement to date.